In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - COG-AHOD2131
Protocol Summary
- Protocol No
- COG-AHOD2131
- Principal Investigator
- Michael Burke
- Phase
- III
- Title
- A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
- Associated Disease(s)
-
Hodgkin's Lymphoma
- Description (Summary)
- The overall goal of this study is to compare the effects, good and/or bad, of brentuximab vedotin and nivolumab (Bv-NIVO) against standard therapy for people with HL to find out which is better.
The first part of treatment on this study involves cancer fighting medicine called chemotherapy. The chemotherapy is 2 cycles of therapy with a commonly used drug combination called ABVD. The treatment on this part of the study takes about 2 months. How the cancer responds to this initial therapy will help to determine the study treatment offered after the first 2 cycles of therapy.
Based on how the cancer responds to the first part of therapy, your study doctors will find out if you have a rapid early response (RER) or a slow early response (SER) to treatment. In addition to your response to the initial therapy, we will use known risk factors to help decide the next part of therapy. The risk factors are called favorable or unfavorable. Favorable risk means your cancer is less likely to come back after treatment while unfavorable risk means your cancer has a greater chance of coming back.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
